[go: up one dir, main page]

ES2095531T3 - Derivados de 17-beta-aril- y 17-beta-heterociclil-5-beta,14-beta-androstano activos sobre el sistema cardiovascular, procesos para su preparacion y composiciones farmaceuticas que contienen los mismos. - Google Patents

Derivados de 17-beta-aril- y 17-beta-heterociclil-5-beta,14-beta-androstano activos sobre el sistema cardiovascular, procesos para su preparacion y composiciones farmaceuticas que contienen los mismos.

Info

Publication number
ES2095531T3
ES2095531T3 ES93112500T ES93112500T ES2095531T3 ES 2095531 T3 ES2095531 T3 ES 2095531T3 ES 93112500 T ES93112500 T ES 93112500T ES 93112500 T ES93112500 T ES 93112500T ES 2095531 T3 ES2095531 T3 ES 2095531T3
Authority
ES
Spain
Prior art keywords
beta
preparation
heterociclil
androstano
aril
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93112500T
Other languages
English (en)
Inventor
Nicoletta Alimirante
Luigi Bernardi
Alberto Cerri
Piero Melloni
Gloria Padoani
Luisa Quadri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of ES2095531T3 publication Critical patent/ES2095531T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE PRESENTAN DERIVADOS DE 17-ARIL Y 17-HETEROCICLIL-5(BETA),14(BETA)ANDROSTANO DE LA FORMULA GENERAL (I): EN DONDE: EL SIMBOLO DE LINEA ONDULADA SIGNIFICA QUE LOS SUSTITUYENTES DE LA POSICION 17 PUEDEN TENER UNA CONFIGURACION O (BETA); EL SIMBOLO DE LINEA RECTA CON UNA DE RAYAS SUPERPUESTA REPRESENTA UN ENLACE SENCILLO O UNO DOBLE; Y, R Y R1 TIENEN EL SIGNIFICADO DADO EN LA DESCRIPCION; UN PROCESO PARA LA PREPARACION DE LOS MISMOS, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN COMO INGREDIENTE ACTIVO Y SU USO EN LA PREPARACION DE UN AGENTE FARMACEUTICO PARA EL TRATAMIENTO DE TRASTORNOS CARDIOVASCULARES TALES COMO COLAPSOS Y LA HIPERTENSION.
ES93112500T 1992-09-29 1993-08-04 Derivados de 17-beta-aril- y 17-beta-heterociclil-5-beta,14-beta-androstano activos sobre el sistema cardiovascular, procesos para su preparacion y composiciones farmaceuticas que contienen los mismos. Expired - Lifetime ES2095531T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4232638A DE4232638C2 (de) 1992-09-29 1992-09-29 17-Phenyl-5beta-14beta-androstanderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen

Publications (1)

Publication Number Publication Date
ES2095531T3 true ES2095531T3 (es) 1997-02-16

Family

ID=6469142

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93112500T Expired - Lifetime ES2095531T3 (es) 1992-09-29 1993-08-04 Derivados de 17-beta-aril- y 17-beta-heterociclil-5-beta,14-beta-androstano activos sobre el sistema cardiovascular, procesos para su preparacion y composiciones farmaceuticas que contienen los mismos.

Country Status (11)

Country Link
US (1) US5567694A (es)
EP (1) EP0590272B1 (es)
JP (1) JPH06192286A (es)
KR (1) KR940007055A (es)
AT (1) ATE147077T1 (es)
CA (1) CA2106917A1 (es)
DE (2) DE4232638C2 (es)
DK (1) DK0590272T3 (es)
ES (1) ES2095531T3 (es)
GR (1) GR3022376T3 (es)
ZA (1) ZA937085B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510340A (en) * 1992-06-12 1996-04-23 Sri International Antihypercholesterolemic compounds and related pharmaceutical compositions and methods of use
DE4232681C2 (de) * 1992-09-29 1994-11-24 Sigma Tau Ind Farmaceuti 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
WO2004089304A2 (en) 2003-04-01 2004-10-21 Hollis-Eden Pharmaceuticals, Inc. Antiandrogens with marginal agonist activity and methods of use
EP1934241B1 (en) * 2005-09-15 2012-11-14 Council of Scientific and Industrial Research Novel series of imidazolyl substituted steroidal and indan-1-one derivatives
MX2009012917A (es) * 2007-06-07 2010-01-14 Sigma Tau Ind Farmaceuti Derivados de 5beta, 14-beta-androestano utiles para el tratamiento de restenosis despues de angioplastia o endoarterectomia y enfermedades debido a la fibrosis de organos.
AU2010227644B2 (en) 2009-03-23 2016-05-19 Cvie Therapeutics Limited 5-beta, 14-beta-androstane derivatives useful for the treatment of proteinuria, glomerulosclerosis and renal failure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2614046C2 (de) * 1976-04-01 1984-08-02 Boehringer Mannheim Gmbh, 6800 Mannheim Neue 17α-Hydroxy-Cardenolid-Glykoside, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
FR2407940A1 (fr) * 1977-11-08 1979-06-01 Roussel Uclaf Nouveaux derives steroides 17 a-aryle, ou 17 a-heteroaryle, leur procede de preparation et leur application comme medicament
DE3223735A1 (de) * 1982-06-25 1983-12-29 Boehringer Mannheim Gmbh, 6800 Mannheim Neue derivate von 17(alpha)-hydroxy-digitoxigenin-digitoxosiden, verfahren zu ihrer herstellung und ihre verwendung als arzneitmittel
JPH0368596A (ja) * 1989-08-09 1991-03-25 Snow Brand Milk Prod Co Ltd １４α‐ヒドロキシ‐４‐アンドロステン‐３，６，１７‐トリオンの製造方法

Also Published As

Publication number Publication date
DE69307071D1 (de) 1997-02-13
HK1005878A1 (en) 1999-01-29
GR3022376T3 (en) 1997-04-30
DE4232638C2 (de) 1994-11-17
EP0590272A2 (en) 1994-04-06
JPH06192286A (ja) 1994-07-12
DE69307071T2 (de) 1997-05-22
DK0590272T3 (da) 1997-04-14
ZA937085B (en) 1994-08-11
EP0590272B1 (en) 1997-01-02
KR940007055A (ko) 1994-04-26
CA2106917A1 (en) 1994-03-30
ATE147077T1 (de) 1997-01-15
DE4232638A1 (de) 1994-03-31
US5567694A (en) 1996-10-22
EP0590272A3 (en) 1994-07-06

Similar Documents

Publication Publication Date Title
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
ES2095432T3 (es) Derivados de 2,4-tiazolidin-diona, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2128552T3 (es) Combinacion de un inhibidor de la biosintesis del colesterol y un inhibidor de la absorcion del colesterol beta-lactama.
MX9202407A (es) Composicion farmaceutica que contiene un compuesto de alilamina como el agente activo y proceso para su preparacion.
ES2180592T3 (es) Formulaciones en aerosol libres de clorofluorocarbonos.
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
ES2040234T3 (es) Derivados del tetrahidronaftaleno y medicamentos que los contienen.
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
ES2084944T3 (es) Amidas terapeuticas.
ES2076935T3 (es) Compuesto de pirazolopiridina y procedimientos para su preparacion.
ES2075202T3 (es) Nuevas arilpiridazinas, su preparacion, su utilizacion, y medicamentos que las contienen.
ES2126766T3 (es) 7-azaindol-3-ilcarboxiamidas de tropilo como agente antitusivo.
DK0548114T5 (da) Mometason-furoat-monohydrat, fremgangsmåde til fremtilling deraf og farmaceutiske præparater indeholdende dette
MX9207494A (es) 4(5)-amino-1,8-naftiridinas substituidas, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
MX9204318A (es) Complejos de derivados de pleuromutilina para su preparacion y composiciones farmaceuticas que los contienen.
MX9303123A (es) Ciclopentano-y-penteno-beta-aminoacidos, procedimiento para su preparacion y medicamentos que los contienen.
MX9301157A (es) Derivados de bencimidazolona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
MX9300628A (es) Nuevos derivados de taxano, procedimiento para su preparacion y composicion farmaceutica que los contiene.
ES2100396T3 (es) Derivados de 17-(3-furil)- y 17-(4-piridazinil)-5beta,14beta-androstano activos sobre el sistema cardiovascular, procesos para su preparacion y composiciones farmaceuticas que los contienen.
ES2095531T3 (es) Derivados de 17-beta-aril- y 17-beta-heterociclil-5-beta,14-beta-androstano activos sobre el sistema cardiovascular, procesos para su preparacion y composiciones farmaceuticas que contienen los mismos.
ES2052484T1 (es) N-(5-tioxo-l-prolil)-l-cisteina, sus derivados, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
ES2145234T3 (es) Derivados de la diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2043943T3 (es) Procedimiento para la preparacion de compuestos con actividad analgesica central.
ES2133918T3 (es) Nuevos esteroides seco-d activos en el sistema cardiovascular y composiciones farmaceuticas que los contienen.
ES483116A1 (es) Procedimiento para la preparacion de derivados de acidos aziridin-2-carboxilicos substituidos en n, inmunoestimulan- tes

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 590272

Country of ref document: ES